If hot flashes or night sweats are the symptom wrecking your day, fezolinetant is worth knowing by its real shape.
It is not hormone therapy. It is not a supplement. It is a prescription, nonhormonal medicine for moderate to severe vasomotor symptoms due to menopause, with current label requirements that make liver testing part of the decision. [1]
The useful question is not "Should every woman try it?" It is "Are hot flashes or night sweats the main problem, and can the monitoring plan be done correctly?"
What fezolinetant treats
Fezolinetant is labeled for moderate to severe vasomotor symptoms due to menopause. That means hot flashes and night sweats. The VEOZAH label describes a 45 mg tablet taken once daily. [1]
That narrow target is a benefit when the symptom pattern is clear. A woman who has disruptive heat surges, sweat, flushing, and sleep interruption may want a nonhormonal prescription path, especially if systemic estrogen is not preferred or is not a good fit.
The same narrow target is also the boundary. Fezolinetant is not a treatment for vaginal dryness, painful sex, recurrent urinary symptoms, bone loss, low desire, weight gain, hair thinning, depression, or all midlife fatigue. Those symptoms can overlap with menopause, but they need their own evaluation and treatment route.
Related reading:
What the trials showed
The two pivotal phase 3 trials were placebo-controlled. They did not test fezolinetant head-to-head against hormone therapy.
In SKYLIGHT 1, women aged 40 to 65 with an average of at least 7 moderate to severe hot flashes per day were randomized to placebo, fezolinetant 30 mg, or fezolinetant 45 mg. With the 45 mg dose, the reduction versus placebo was 2.07 episodes per day at week 4 and 2.55 episodes per day at week 12. Improvements were observed after 1 week and maintained over 52 weeks. [3]
SKYLIGHT 2 found a similar pattern. With the 45 mg dose, fezolinetant reduced vasomotor symptom frequency versus placebo by 2.55 episodes per day at week 4 and 2.53 episodes per day at week 12. Serious treatment-emergent adverse events were infrequent in the placebo-controlled period. [4]
The practical translation is measured in daily episodes. If a woman is having 8 to 10 moderate or severe hot flashes a day, the trial signal is about 2 to 3 fewer episodes per day beyond placebo, not the complete removal of symptoms for everyone.
Why liver testing is part of the treatment
The current VEOZAH label includes a boxed warning for risks of hepatotoxicity. DailyMed lists the label as updated February 26, 2026, with the boxed warning added as a major change in December 2024. [1]
The label says hepatic laboratory tests should be done before treatment starts, monthly for the first 3 months, and again at months 6 and 9. It also says not to start VEOZAH when either aminotransferase is at least 2 times the upper limit of normal or total bilirubin is at least 2 times the upper limit of normal. [1]
The Food and Drug Administration safety communication describes a postmarketing case of serious drug-induced liver injury that developed within 40 days of starting Veozah and improved after the medicine was stopped. [2]
That warning does not mean fezolinetant has no place. It means the monitoring plan is not optional.
Elinzanetant is a newer option, not another name for fezolinetant
Elinzanetant (Lynkuet) is another FDA-labeled nonhormonal prescription medicine for moderate to severe vasomotor symptoms due to menopause. It antagonizes both neurokinin 1 (NK1) and neurokinin 3 (NK3) receptors; fezolinetant targets NK3. The medicines should not be treated as interchangeable because their doses, interaction checks, warnings, and monitoring schedules differ. [1] [7]
The current Lynkuet label requires baseline hepatic tests and a follow-up transaminase evaluation at 3 months. In the three placebo-controlled OASIS trials, ALT or AST elevations of at least 3 times the upper limit of normal occurred in 0.6% of participants receiving Lynkuet and 0.4% receiving placebo through 12 weeks. The label also highlights daytime impairment from nervous-system effects, pregnancy loss, seizure risk, and CYP3A4 interactions. [7]
That is less scheduled liver testing than the current Veozah label, but it is not baseline-only testing and it is not a reason to skip symptom-triggered evaluation. The practical comparison is drug-specific: which mechanism, interaction profile, adverse effects, and monitoring plan best fit the individual patient?
Who may be a better fit
| Clinical question | Fezolinetant may fit when | Another route may fit when |
|---|---|---|
| Main symptom | Moderate to severe hot flashes or night sweats are the dominant problem. | The main concern is vaginal dryness, painful sex, urinary symptoms, mood, libido, weight, bone loss, or fatigue. |
| Hormone preference | A nonhormonal prescription option is preferred, or systemic estrogen is not appropriate. | Hormone therapy is desired and the symptom pattern, age, time since menopause, uterus status, and risk profile make it appropriate. |
| Monitoring | Baseline and follow-up liver testing can be completed on schedule. | Liver testing cannot be completed, baseline labs are abnormal, or contraindications are present. |
| Evidence expectation | The goal is fewer vasomotor episodes versus placebo. | The goal is broader menopause symptom coverage, genitourinary treatment, sleep diagnosis, metabolic treatment, or another specific problem. |
The 2023 Menopause Society nonhormone statement lists fezolinetant as a Level I nonhormonal option for vasomotor symptoms. The same statement says hormone therapy remains the most effective treatment for vasomotor symptoms and should be considered for menopausal women within 10 years of the final menstrual period when they are appropriate candidates. [5]
That is the right frame: choose the route based on symptom target, contraindications, personal preference, and monitoring capacity.
When to pause before starting
Fezolinetant should not be handled like an over-the-counter hot-flash aid. The label lists clear contraindications and stopping rules. [1]
| Pause point | Why it matters |
|---|---|
| Known cirrhosis | The label lists known cirrhosis as a contraindication. |
| Severe kidney impairment or end-stage kidney disease | The label lists severe renal impairment and end-stage renal disease as contraindications. |
| CYP1A2 inhibitor use | Concomitant CYP1A2 inhibitor use is contraindicated because it can raise exposure. |
| Liver tests already elevated | The label says not to start if either aminotransferase or total bilirubin is at least 2 times the upper limit of normal. |
| New fatigue, appetite loss, nausea, vomiting, itching, yellow skin or eyes, pale stool, dark urine, or abdominal pain | The label says to stop immediately and seek medical attention with liver laboratory testing if symptoms suggest liver injury. |
| Symptoms are not mainly hot flashes or night sweats | Fezolinetant targets vasomotor symptoms, so the main symptom may need a different treatment path. |
How it differs from hormone therapy
Hormone therapy and fezolinetant should not be collapsed into one ladder where one is automatically stronger or safer for every person.
Hormone therapy can be a high-evidence treatment for hot flashes and night sweats in selected women, and it may address some additional menopause-related targets depending on formulation. It also requires a separate risk-benefit review that includes age, time since menopause, uterus status, clot and stroke risk, breast cancer history, liver disease, blood pressure, route, dose, and patient priorities. [6]
Fezolinetant avoids estrogen exposure and targets the neurokinin 3 receptor pathway. Its tradeoff is narrower symptom coverage plus required liver screening and follow-up testing. [1]
The cleaner visit question is: "Which route fits my symptom target and my risk profile?"
What to ask a clinician
Ask:
- Are my symptoms clearly moderate to severe vasomotor symptoms, or could another sleep, thyroid, medication, infection, mood, or metabolic issue be part of the picture?
- Do my baseline liver tests, kidney function, and medication list make fezolinetant an option?
- Which exact liver tests are needed before treatment, during months 1, 2, 3, 6, and 9, and if symptoms appear?
- Which symptoms mean I should stop the medicine and seek medical care?
- If my hot flashes improve but vaginal, urinary, libido, mood, weight, or sleep symptoms remain, what is the separate plan?
- How does fezolinetant compare with elinzanetant, hormone therapy, gabapentin, antidepressant-class options, oxybutynin, behavioral therapies, or no medication for my history?
Bottom line
Fezolinetant is a real nonhormonal prescription option for moderate to severe hot flashes and night sweats due to menopause. Its evidence is strongest for fewer daily vasomotor episodes versus placebo.
The decision should include the benefit and the safety workflow together: symptom fit, baseline labs, contraindications, follow-up liver testing, and a plan for symptoms that fezolinetant does not treat.
References
[1] DailyMed. VEOZAH (fezolinetant) prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cae9f798-24f9-4580-a4fc-e6c710cbda3c
[2] FDA. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. https://www.fda.gov/drugs/drug-safety-communications/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due
[3] Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091-1102. doi:10.1016/s0140-6736(23)00085-5 https://pubmed.ncbi.nlm.nih.gov/36924778/
[4] Johnson KA, Martin N, Nappi RE, et al. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. J Clin Endocrinol Metab. 2023;108(8):1981-1997. doi:10.1210/clinem/dgad058 https://pubmed.ncbi.nlm.nih.gov/36734148/
[5] New Collective Author. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. doi:10.1097/gme.0000000000002200 https://pubmed.ncbi.nlm.nih.gov/37252752/
[6] “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/gme.0000000000002028 https://pubmed.ncbi.nlm.nih.gov/35797481/
[7] DailyMed. LYNKUET (elinzanetant) prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f42884ff-7dff-419c-8a0c-affe2ed73818